(Q28195458)

2

object named as

Kandice Kottke-Marchant

0 references

author name string

Patricia A Gum

1

0 references

Patricia A Welsh

3

0 references

Jennifer White

Journal of the American College of Cardiology

4

0 references

language of work or name

English

0 references

publication date

19 March 2003

0 references

published in

0 references

volume

41

0 references

issue

6

0 references

page(s)

961-5

0 references

cites work

Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021

Aspirin response and failure in cerebral infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021

Effects of acetylsalicylic acid in stroke patients evidence of nonresponders in a subpopulation of treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021

Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of eryt

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021

Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021

Sex difference in antithrombotic effect of aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021

Development of aspirin resistance in persons with previous ischemic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021

Differential Suppression of Thromboxane Biosynthesis by Indobufen and Aspirin in Patients With Unstable Angina

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021

Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021

Results of CURE trial for acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2802%2903014-0

7 January 2021